Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Healio13h
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
The Pharma Letter16h
BioAge rings the changes after azelaprag failure
A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...
pharmaphorum17h
Ozempic is first GLP-1 drug FDA-approved for kidney disease
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
FiercePharma20h
Hims & Hers tackles pharma industry drug pricing in Super Bowl ad for compounded GLP-1s
Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...
ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.